Zynex, Inc.
Zynex, Inc. (ZYXI) Stock Competitors & Peer Comparison
See (ZYXI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZYXI | $0.13 | +140.38% | 3.8M | -0.05 | -$2.41 | N/A |
| MCK | $828.32 | +0.03% | 101.4B | 23.92 | $34.61 | +0.39% |
| COR | $310.16 | +0.64% | 60.3B | 37.28 | $8.32 | +0.74% |
| CAH | $202.34 | +1.25% | 47.6B | 29.11 | $6.95 | +1.01% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $77.20 | -0.44% | 8.9B | 23.61 | $3.27 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| PBH | $58.30 | -1.09% | 2.8B | 15.07 | $3.87 | N/A |
| GRDN | $37.93 | +0.96% | 2.4B | 48.67 | $0.78 | N/A |
| ACH | $3.42 | +3.64% | 261.8M | -2.56 | -$1.34 | N/A |
Stock Comparison
ZYXI vs MCK Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, MCK has a market cap of 101.4B. Regarding current trading prices, ZYXI is priced at $0.13, while MCK trades at $828.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas MCK's P/E ratio is 23.92. In terms of profitability, ZYXI's ROE is -18.07%, compared to MCK's ROE of -2.45%. Regarding short-term risk, ZYXI is less volatile compared to MCK. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check MCK's competition here
ZYXI vs COR Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, COR has a market cap of 60.3B. Regarding current trading prices, ZYXI is priced at $0.13, while COR trades at $310.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas COR's P/E ratio is 37.28. In terms of profitability, ZYXI's ROE is -18.07%, compared to COR's ROE of +1.01%. Regarding short-term risk, ZYXI is less volatile compared to COR. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check COR's competition here
ZYXI vs CAH Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, CAH has a market cap of 47.6B. Regarding current trading prices, ZYXI is priced at $0.13, while CAH trades at $202.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas CAH's P/E ratio is 29.11. In terms of profitability, ZYXI's ROE is -18.07%, compared to CAH's ROE of -0.59%. Regarding short-term risk, ZYXI is less volatile compared to CAH. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check CAH's competition here
ZYXI vs ABC Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, ZYXI is priced at $0.13, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas ABC's P/E ratio is 21.92. In terms of profitability, ZYXI's ROE is -18.07%, compared to ABC's ROE of +1.01%. Regarding short-term risk, ZYXI is less volatile compared to ABC. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check ABC's competition here
ZYXI vs HSIC Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, HSIC has a market cap of 8.9B. Regarding current trading prices, ZYXI is priced at $0.13, while HSIC trades at $77.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas HSIC's P/E ratio is 23.61. In terms of profitability, ZYXI's ROE is -18.07%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, ZYXI is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check HSIC's competition here
ZYXI vs PDCO Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, ZYXI is priced at $0.13, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas PDCO's P/E ratio is 20.48. In terms of profitability, ZYXI's ROE is -18.07%, compared to PDCO's ROE of +0.06%. Regarding short-term risk, ZYXI and PDCO have similar daily volatility (0.00).Check PDCO's competition here
ZYXI vs PBH Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, PBH has a market cap of 2.8B. Regarding current trading prices, ZYXI is priced at $0.13, while PBH trades at $58.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas PBH's P/E ratio is 15.07. In terms of profitability, ZYXI's ROE is -18.07%, compared to PBH's ROE of +0.10%. Regarding short-term risk, ZYXI is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check PBH's competition here
ZYXI vs GRDN Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, GRDN has a market cap of 2.4B. Regarding current trading prices, ZYXI is priced at $0.13, while GRDN trades at $37.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas GRDN's P/E ratio is 48.67. In terms of profitability, ZYXI's ROE is -18.07%, compared to GRDN's ROE of +0.28%. Regarding short-term risk, ZYXI is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check GRDN's competition here
ZYXI vs ACH Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, ACH has a market cap of 261.8M. Regarding current trading prices, ZYXI is priced at $0.13, while ACH trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas ACH's P/E ratio is -2.56. In terms of profitability, ZYXI's ROE is -18.07%, compared to ACH's ROE of +7.33%. Regarding short-term risk, ZYXI is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check ACH's competition here
ZYXI vs OMI Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, ZYXI is priced at $0.13, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas OMI's P/E ratio is -0.47. In terms of profitability, ZYXI's ROE is -18.07%, compared to OMI's ROE of +7.33%. Regarding short-term risk, ZYXI is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check OMI's competition here
ZYXI vs GEG Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, GEG has a market cap of 57.6M. Regarding current trading prices, ZYXI is priced at $0.13, while GEG trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas GEG's P/E ratio is -4.26. In terms of profitability, ZYXI's ROE is -18.07%, compared to GEG's ROE of -0.21%. Regarding short-term risk, ZYXI is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check GEG's competition here
ZYXI vs HX Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, ZYXI is priced at $0.13, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas HX's P/E ratio is -1.84. In terms of profitability, ZYXI's ROE is -18.07%, compared to HX's ROE of -1.07%. Regarding short-term risk, ZYXI is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check HX's competition here
ZYXI vs WGRX Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, WGRX has a market cap of 8.8M. Regarding current trading prices, ZYXI is priced at $0.13, while WGRX trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas WGRX's P/E ratio is -0.09. In terms of profitability, ZYXI's ROE is -18.07%, compared to WGRX's ROE of +1417.60%. Regarding short-term risk, ZYXI is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check WGRX's competition here
ZYXI vs SNYR Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, SNYR has a market cap of 3.8M. Regarding current trading prices, ZYXI is priced at $0.13, while SNYR trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas SNYR's P/E ratio is -0.31. In terms of profitability, ZYXI's ROE is -18.07%, compared to SNYR's ROE of +0.83%. Regarding short-term risk, ZYXI is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check SNYR's competition here
ZYXI vs MEHA Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, MEHA has a market cap of 749.3K. Regarding current trading prices, ZYXI is priced at $0.13, while MEHA trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas MEHA's P/E ratio is 10.88. In terms of profitability, ZYXI's ROE is -18.07%, compared to MEHA's ROE of +1.19%. Regarding short-term risk, ZYXI is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check MEHA's competition here
ZYXI vs RDGT Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, RDGT has a market cap of 455. Regarding current trading prices, ZYXI is priced at $0.13, while RDGT trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas RDGT's P/E ratio is -0.03. In terms of profitability, ZYXI's ROE is -18.07%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, ZYXI is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check RDGT's competition here
ZYXI vs CVET Comparison April 2026
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 3.8M. In comparison, CVET has a market cap of 0. Regarding current trading prices, ZYXI is priced at $0.13, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -0.05, whereas CVET's P/E ratio is -69.97. In terms of profitability, ZYXI's ROE is -18.07%, compared to CVET's ROE of -0.06%. Regarding short-term risk, ZYXI is less volatile compared to CVET. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check CVET's competition here